Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-103
- Development stage
- Preclinical
- Lead developer
- Kuwait Foundation for the Advancement of Sciences
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral, Subcutaneous, Intravenous, Intraperitoneal, Intratumoral, Intranasal, Inhalation, Intrathecal, Intramuscular, Oral, Intradermal
01
Overview
miR-103 is a microRNA that serves as a key epigenetic regulator of triglyceride metabolism and lipid homeostasis. It exerts its therapeutic potential by suppressing de novo lipogenesis through the direct targeting of Fatty Acid Synthase (FASN) and Stearoyl-CoA Desaturase 1 (SCD1). Furthermore, miR-103 modulates the ANGPTL8/ANGPTL3 axis by repressing Angiopoietin-like protein 8 (ANGPTL8) expression, which subsequently increases Lipoprotein Lipase (LPL) activity and reduces plasma triglyceride levels. Research indicates that miR-103 is significantly downregulated in obese individuals, and its restoration via overexpression or mimicry is being investigated as a treatment for dyslipidemia and obesity-associated metabolic dysfunction.
- Other names
- microRNA-103microRNA103microRNA 103
02
Targets
ANGPTL8 (Developmentally regulated endothelial locus 1)ACOX1 (Peroxisomal acyl-CoA oxidase 1)SREBP-1 / SREBF1 (SREBP-1)SCD1 (Stearoyl-CoA desaturase 1)FASN (Fatty acid synthase)FABP1 (Fatty acid-binding protein 1)
Beyond the preview
Go deeper on miR-103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-103.